Welcome to our dedicated page for Third Harmonic Bio news (Ticker: THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.
Third Harmonic Bio, Inc. (Nasdaq: THRD) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergy and inflammation. The cornerstone of their research is the KIT inhibitor, a cell surface receptor that regulates mast cells, which play a crucial role in allergic and inflammatory responses.
The company’s lead product candidate, THB001, marked a significant milestone as the first highly selective, oral small-molecule KIT inhibitor to enter clinical development. Despite early termination of its Phase 1b clinical trial due to observed liver toxicity in a limited number of patients, THB001 demonstrated promising clinical benefits in treating chronic inducible urticaria, a condition characterized by chronic, often painful hives.
Building on the insights from THB001, Third Harmonic Bio is now advancing THB335, a next-generation KIT inhibitor with structural modifications aimed at mitigating the hepatotoxicity risks observed in its predecessor. THB335 retains the potency and selectivity of THB001 and is anticipated to offer a safer metabolic profile. The company has planned to initiate clinical trials of THB335 in the first half of 2024, focusing initially on chronic spontaneous urticaria with potential expansion to other mast cell-mediated inflammatory disorders.
Third Harmonic Bio's innovative approach extends to a broad range of dermatologic, respiratory, and gastrointestinal diseases. By focusing on highly selective, oral small-molecule inhibitors, the company aims to provide effective, easy-to-administer treatments that could revolutionize care for patients with mast cell-mediated inflammatory conditions.
Financially, the company is robust with $273.9 million in cash and cash equivalents as of September 30, 2023, sufficient to fund operations through at least 2025. Recent corporate achievements include the FDA clearance of their IND application for THB335 and the initiation of a Phase 1 clinical trial in healthy volunteers.
The executive team, led by CEO Natalie Holles, has been strengthened with key appointments, including a new Chief Scientific Officer, Chief Non-Clinical Development Officer, and Chief Development Operations Officer, each bringing extensive experience in drug discovery and development.
For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Third Harmonic Bio (Nasdaq: THRD) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Chris Murphy, Chief Financial and Business Officer, will engage in a fireside chat on December 4, 2024, at 9:35 a.m. The company, which focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide a live audio webcast accessible through their website's Investors & Media section. The replay will remain available for 90 days after the event.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases, has announced its participation in two major investor conferences this November. Natalie Holles, CEO, will present at the Stifel 2024 Healthcare Conference on November 19 at 3:00 p.m. EST, while Chris Murphy, CFO, will speak at the Jefferies London Healthcare Conference on the same day at 11:00 a.m. GMT. Live audio webcasts will be available on Third Harmonic's website, with replays accessible for 90 days after the events.
Third Harmonic Bio (Nasdaq: THRD) reported Q3 2024 financial results, highlighting its Phase 1 SAD/MAD clinical trial of THB335 progressing towards data readout in Q1 2025. The company maintains a strong financial position with $296.1 million in cash and equivalents. Q3 2024 saw increased R&D expenses of $11.3 million, up from $6.0 million in Q3 2023, while net loss widened to $13.8 million from $7.3 million year-over-year. The company expects current cash reserves to fund operations through at least 2026.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2024. CEO Natalie Holles will engage in fireside chats at the following events:
- Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
- TD Cowen Virtual Chronic Urticaria Summit on September 20, 2024, at 3:00 p.m. ET
The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these sessions on its website. Archived replays will be available for 90 days after the events.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. CEO Natalie Holles will engage in fireside chats at the following events:
- Morgan Stanley 22nd Healthcare Conference on September 4, 2024, at 9:15 a.m. ET
- Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these presentations. These webcasts will be accessible through the Investors & Media section of Third Harmonic Bio's website, with archived replays available for 90 days after each event.
Third Harmonic Bio (Nasdaq: THRD) announced its Q2 2024 financial results and provided a business update. The company's Phase 1 SAD/MAD clinical trial for THB335 is progressing well, with results now expected in Q1 2025. Third Harmonic Bio reported a strong financial position with $255.3 million in cash and cash equivalents as of June 30, 2024, which is expected to fund operations through at least 2026.
Key financial highlights include:
- R&D expenses increased to $8.4 million for Q2 2024, up from $5.3 million in Q2 2023
- G&A expenses rose slightly to $5.7 million in Q2 2024 from $5.4 million in Q2 2023
- Net loss for Q2 2024 increased to $10.7 million, compared to $7.6 million in Q2 2023
The company is preparing to advance THB335 into a Phase 2 clinical trial for chronic spontaneous urticaria, with plans to expand into additional mast cell-mediated diseases.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, announced that its CEO, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET.
The event will be webcast live on the Third Harmonic Bio website, with a replay available for 90 days post-event.
The company focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.
Third Harmonic Bio (Nasdaq: THRD) announced its Q1 2024 financial results and business updates. The U.S. FDA cleared its IND application for THB335, enabling a Phase 1 clinical trial focusing on chronic spontaneous urticaria. Results are expected in the first half of 2025. The company strengthened its leadership, appointing Christopher J. Dinsmore, Ph.D., as Chief Scientific Officer, Dennis Dean, Ph.D., as Chief Non-Clinical Development Officer, and promoting Jennifer Dittman to Chief Development Operations Officer. Financially, the company reported cash and equivalents of $262.8 million, decreased R&D expenses to $6.2 million, and G&A expenses to $5.1 million. Net loss decreased to $7.9 million from $9.1 million a year earlier.
FAQ
What is the current stock price of Third Harmonic Bio (THRD)?
What is the market cap of Third Harmonic Bio (THRD)?
What does Third Harmonic Bio, Inc. do?
What is THB001?
Why was the clinical trial for THB001 discontinued?
What is THB335?
When will THB335 enter clinical trials?
What diseases could THB335 potentially treat?
How is Third Harmonic Bio financially positioned?
Who are the key executives at Third Harmonic Bio?
Where can I find more information about Third Harmonic Bio?
What are the future prospects for Third Harmonic Bio?
